The New Nation - Internet Edition

Sanofi-aventis Bangladesh Limited is the new entity that has been formed through the amalgamation of three legal entities-Aventis Limited, Fisons (Bangladesh) Limited and Hoechst Marion Roussel Limited. The legal integration process has taken few years after the global merger between sanofi-synthalebo and Aventis in September 2004 and finally the existing three legal entities have amalgamated as Sanofi-Aventis Bangladesh Limited on December 11, 2007. The new name of the of the newly amalgamated company has been registered with the Registrar of Joint Stock Companies and Firms on January 31, 2008.Sanofi-aventis, a leading global pharmaceutical group, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. The Group is present in more than 100 countries with around 11,000 scientists and more than 100,000 employees worldwide. Sanofi-aventis has a portfolio containing a wide range of innovative vaccines and medicines, particularly in its areas of excellence and expertise such as thrombosis, diabetes, cardiovascular diseases, oncology, disorders of the central nervous system, vaccines and internal medicine. Sanofi-aventis Bangladesh Limited has a diverse portfolio of products ranging from widespread names like Fimoxyl, Sefrad, Clexane, Amaryl, Profenid etc to traditional names like Flagyl, Stemetil, Oracyn-K, Frisium etc to revolutionary original research product like Eloxatin, Taxotere and Lantus.

Sanofi-aventis Bangladesh Limited, being the largest global pharmaceutical company in Bangladesh, is making a considerable contribution in the national economy of Bangladesh in addition to the technology transfer in the local pharmaceutical field. Apart from that, sanofi-aventis Bangladesh Limited is strongly committed as a socially responsible organization. Projects like "My child matters" carried out in partnership with UICC (International Union against Cancer) to fight against child cancer is one of the numerous examples of the organization's commitment to the society.

Sanofi-aventis Bangladesh Limited contributed a total of Taka 28.4 crore to the national exchequer in the form of Tax, VAT, custom duties etc. in 2007. The Government of Bangladesh holds 45% shares in the company.

All the business transactions and communications will now be carried out in the name of sanofi-aventis Bangladesh Limited. Doctors, chemists and institutions and other key stakeholders have been duly communicated about the merger and have been requested to update their records adapting to the new entity sanofi-aventis Bangladesh Limited. Decision about the legal merger has also been communicated to all employees through internal events.

Sanofi-aventis Bangladesh Limited has always been committed in meeting and exceeding the stakeholders' expectations and earning the respect of various institutions as the long-term professional partner of choice.